Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AriBio logo — Developing novel therapies for neurodegenerative diseases.

AriBio

Developing novel therapies for neurodegenerative diseases.

Founded 2010 Korea South Korea South 37 employees Venture round Total: $100.00B AI, Biotechnology

General Information

Company Name AriBio
Founded Year 2010
Location Korea South Korea South
Founders / Decision Makers
Team member
Employees 37
Industries AI, Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with AriBio. To contact AriBio, visit aribio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AriBio compare?

A PDF of AriBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AriBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AriBio

AriBio is a clinical-stage biotech company located in Seongnam, South Korea and was founded in 2010. The company's slogan "Developing novel therapies for neurodegenerative diseases" encompasses its core mission. With a US office based in San Diego overseeing global clinical operations and regulatory affairs, AriBio is strategically positioned for international growth. The company's lead asset, AR1001, is set to enter a global phase 3 program this year, indicating a significant milestone in its development. AriBio recently secured a noteworthy KRW100.00BVenture Round investment on 18 February 2022, with major contributions from Milestone, Meritz Securities, and Lambda Asset Management. This investment not only validates the company's potential but also provides substantial support for its upcoming endeavours in the biotechnology industry. AriBio's focus on addressing neurodegenerative diseases positions it as a promising player in the ongoing quest for novel therapies in this critical medical field.

Taxonomy: neurodegenerative diseases, biotech, clinical-stage, therapeutics, novel therapies, global phase 3 program, AR1001, Seongnam, San Diego, regulatory affairs, clinical operations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round KRW100.00B 3
Meritz Securities Lambda Asset Management 上海理成资产管理有限公司
Meritz Securities, Lambda Asset Management +1
18 Feb 2022

AriBio Alternatives & Competitors

View All Alternatives
AriBio vs
GEn1E Lifesciences Inc.
GEn1E Lifesciences Inc. United States

Clinical-stage, Phase 2 company accelerating novel Precision Therapies for I&I and Rare Diseases usi...

Series A
18 employees
AI, Biotechnology
AriBio vs
DeepCure
DeepCure United States

Reimagining small molecule therapies for immune diseases

Series A
28 employees
AI, Biotechnology
AriBio vs
Arctoris
Arctoris United Kingdom

Arctoris is a tech-enabled Partnership Research Organization (PRO) headquartered in Oxford, UK.

38 employees
AI, Automation
View all alternatives

FAQ About AriBio

Developing novel therapies for neurodegenerative diseases.
AriBio was founded in 2010.
AriBio is headquartered in Korea South.
AriBio operates in AI and Biotechnology. Its work centres on neurodegenerative diseases, biotech, clinical-stage and therapeutics.
AriBio has approximately 37 employees.
AriBio has completed 1 funding round, raising a total of $100.00B. The latest funding stage is Venture round.
Top alternatives and competitors to AriBio include GEn1E Lifesciences Inc., DeepCure, Arctoris, ArisGlobal. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AriBio and GEn1E Lifesciences Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AriBio, https://bouncewatch.com/company/aribio, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes